review follow
arqul report financi result provid updat
clinical/busi oper manag continu execut across portfolio
pois meaning clinic potenti regulatori updat
miransertib enrol patient across registr arm ps
recent updat aacr-nci-eortc tripl meet
call investor focu remain continu treat eight patient
sub-typ keenli focus upcom abstract
releas next week nov help frame setup upcom meet
add approxim two month follow-up sinc eha given arqul pipelin
execut across multipl front updat model stay bullish
stay tune upcom abstract could establish size
scope data avail time meet manag highlight
juli submiss incorpor approxim two month follow-up post-eha
patient number small focus durabl
four report pr mutant cll patient month
end-of-phas meet schedul updat arqul
meet agenc schedul near term could yield updat
meet updat outsid base case interact could
establish whether progress straight pivot btk-mutat
posit patient potenti pivot program richter transform
competit focu remain venetoclax yet peer said
believ updat meet revers btk peer snss apto
could initi earli comparison thu far patient-experi
post-venetoclax among roughli one-third enrol patient also
look updat on-go preclin combin work
patient pivot alreadi dose impress enrol
ps moreov fourth compassionate-us
cohort could maxim treatment experi safeti perspect base
miransertib first-in-class/best-in-class potenti enthusiasm patient/
physician commun anticip enrol continu apac heed
manag commentari logist rather patient identif
updat model follow result updat model
quarterli estim highlight sector compress previous
coverag univers believ breadth arqul clinic pipelin offset
chang multipl arqul report cash equival market
secur balanc million expect provid runway
year price histori arql
molecul therapeut treat cancer
rare diseas
develop
analyst certif import disclosur see disclosur
miransertib arq approv variou rare diseas
overgrowth syndrom
arq approv variou leukemia/lymphoma indic
arq continu demonstr potenti next-gener
akt inhibitor potenti advanc oncolog indic
rate arqul arql outperform price
target impress compani compet
kinas inhibitor experienc manag team
believ one-two punch compani rare disease/
oncolog franchis arq akt inhibitor blue-
sky scenario revers btk-inhibitor arq
creat substanti valu sharehold near- mid-
abstract releas public et
execut clinic develop plan miransertib
proteus/pro present miransertib phase expans studi
endometri cancer announc futur plan
registr trial miransertib updat akt data solid tumor
feedback fda registr trial design
arq move quickli mid/late-stag develop next-
competitor arq revers btk inhibitor space fail
develop demonstr lengthen develop time vs
kinas inhibitor brought clinic arql
arq akt inhibit demonstr reduc potenti
variou rare diseas oncolog disord
arq demonstr potenti btk inhibit
analog ibrutinib/acalabrutinib
valu arq rare overgrowth diseas appli multipl estim world-wide sale
discount annual assum probabl market valu arq b-cell malign appli
multipl estim world-wide sale discount annual assum probabl market
pipelin program make remain price target
downsid risk outperform rate pt includ clinic failur arq arq phase trial later studi
emerg unaccept side effect failur show competit advantag vs product develop inabl advanc
pipelin product addit risk includ clinic regulatori commerci intellectu properti manufactur competit
strateg financ trade liquid small-capit risk
fulli dilut share productww sale yeardiscount ratesal multipleprob marketnpvrisk-adj npvcommentsarq rate roe nbi index bbg arq approv us ex-usarq rate roe nbi index bbg arq approv us equiv pipelin valu akt inhibitor oncologytot arqul inc
arqul statement million except per share sales- research develop total research gener administr restructur costs- total oper oper interest interest expense- incom total incom loss incom unreal gain market securities- provis incom taxes- net incom dilut share outstand arql outperform
stock price compani mention report
